Thursday, November 16, 2017 4:28:39 PM
No CEO, no leadership, no clear path, and a recently FAILED clinical trial. This simply states that as of right now, they don't know where they are going with the company. You're right in that they are two separate companies working on two separate timelines. Unfortunately this will likely head back to 5-8 cents because there is no clearly defined plan of attack. Even those the technology is similar, without a plan, and someone to actually direct it, we know that there is nothing to sustain a SP increase.
But like Spliffy has stated, it's worth keeping an eye on, but VERY risky at this point. Maybe Cannabix management knew that if they had two companies doing well that it would create an issue legally, so they took the one succeeding an went with it.
And lastly... why did this stock just shoot above 20 cents Canadian for absolutely zero reason...? I mean I am not complaining... but I don't understand.
But like Spliffy has stated, it's worth keeping an eye on, but VERY risky at this point. Maybe Cannabix management knew that if they had two companies doing well that it would create an issue legally, so they took the one succeeding an went with it.
And lastly... why did this stock just shoot above 20 cents Canadian for absolutely zero reason...? I mean I am not complaining... but I don't understand.
Recent AGNPF News
- Algernon Health Announces Proposed Name Change to “Grey Matters Health Inc.” and a 10:1 Share Consolidation • GlobeNewswire Inc. • 03/31/2026 11:09:55 PM
- Algernon Health Announces NOVASCAN NEUROIMAGING CLINICS™ as the New Brand Name for its U.S. Brain PET Scanning Centers • GlobeNewswire Inc. • 03/25/2026 11:00:00 AM
- Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- Algernon Announces Additional Increase to Private Placement Financing to $858,000 and Final Closing of the Financing • GlobeNewswire Inc. • 12/31/2025 09:01:00 PM
- Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche • GlobeNewswire Inc. • 12/23/2025 09:01:00 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 12/09/2025 05:01:20 PM
- Algernon Closes Second Tranche of Private Placement Financing • GlobeNewswire Inc. • 11/29/2025 12:51:39 AM
- Algernon Health and American Molecular Imaging Announce Strategic Business and USD $500K Investment Agreement • GlobeNewswire Inc. • 11/17/2025 12:00:00 PM
- Algernon Closes First Tranche of its Recently Announced Private Placement Financing • GlobeNewswire Inc. • 11/15/2025 12:55:26 AM
- Algernon Health Announces Private Placement • GlobeNewswire Inc. • 11/06/2025 12:04:28 PM
- Algernon Pharmaceuticals Completes Name Change to Algernon Health • GlobeNewswire Inc. • 10/15/2025 11:00:00 AM
- Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection • GlobeNewswire Inc. • 09/25/2025 11:00:00 AM
- Algernon Announces Preferred Share Class Approved at Annual and Special Meeting • GlobeNewswire Inc. • 09/19/2025 08:39:57 PM
